Alcon
Search results
At Galderma, we embrace these differences and offer cutting-edge, premium brands that fit people's individual needs, across the full spectrum of dermatology through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Galderma S.A. is a Swiss pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé , it has been held by a consortium of private institutional investors since 2019.
Galderma is the pure-play dermatology category leader, committed to advancing dermatology for every skin story. Leveraging our unique 40-year heritage of leading science-based innovation, we deliver a synergistic portfolio of flagship brands and services that span the full spectrum of dermatology.
Galderma is the leading company solely dedicated to the body’s largest organ: the skin. We are strategically positioned in resilient, highly attractive and consumer-focused sub-segments of Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Galderma is a focused dermatology company which started in 1981. Galderma is committed to the healthcare community by partnering with healthcare professionals. We provide prescription drugs and aesthetic solutions and go beyond treating skin problems by delivering safe and efficient quality treatments to meet the skin health needs of people ...
Discover the exclusive aesthetics portfolio of dermal fillers, toxins, the original skinbooster and the original collagen biostimulator from Galderma.
Galderma | 373,722 followers on LinkedIn. We are advancing dermatology for every skin story | Galderma is the leading company solely dedicated to skin and advancing the future of dermatology.
Aug 5, 2024 · L’Oréal has acquired a 10 per cent stake in newly listed dermatology company Galderma, in a move that takes the beauty group back into the market for anti-wrinkle injectables and fillers after ...
Nov 8, 2021 · Galderma, the Swiss skincare specialist, has begun talks with international investors for a possible $22bn initial public offering in the first half of next year.
The Investor Relations website contains information about Galderma's business for stockholders, potential investors, and financial analysts.
